“The promise for patients has never been better from a scientific point of view,” said BIO CEO and former Member of Congress Jim Greenwood, speaking at the 22nd BIO CEO & Investor Conference in New York. “But it’s the worst of times politically.” Specifically: There are “mountains of political…

The 22nd annual BIO CEO & Investor Forum kicked off today with a Welcome and Update on BIO's 2020 Initiatives on Behalf of the Industry given by Jeremy Levin, CEO of Ovid Therapeutics Chair of the Board of Directors of BIO. The industry was established in 1970’s during an era of bipartisan…

For nearly two decades, the BIO World Congress has served as a catalyst to the growth and evolution of the bioeconomy. From the conversations started in BIO One-on-One PartneringTM that have led to critical partnerships, to the emerging company presentations that spurred investment, the conference…

For the first time ever, BIO took a comprehensive look at the state of diversity and inclusion in the biotech industry. The findings are in a newly released report, “Measuring Diversity in the Biotech Industry: Building an Inclusive Workforce.”  Image …

Jennifer Bright with the Innovation and Value Initiative recently wrote for Morning Consult that the U.S. is “engaged in the challenging but important conversation about how to assess the value of pharmaceuticals.”  It’s a conversation that should be transparent and open to everyone,…

This week, Congress is expected to consider a USMCA trade agreement that does NOT include stronger IP protections for American innovators who develop biologic medicines. While the removal of these provisions is being hailed as a defeat for Big Pharma, here are three key points to keep in mind as…

By 2040, experts say the number of yearly cancer cases in Africa will double. In 2018 alone, cancer deaths in Africa (over 530,000) were 30 percent higher than deaths from malaria. Clearly, a shift in disease burdens has taken place on the continent. Biotechnology and pharmaceutical companies are…

Welcome to the all-new BIO.org! BIO.org is now your one-stop-shop for everything BIO, from information and resources on our advocacy and policy work, to everything you need to know about BIO events.  For the first time, under the same “roof,” we have you covered from savings on critical items…

Writing for Morning Consult, BIO’s Jim Greenwood discusses the challenges of developing novel antibiotics and highlights the urgent need for policies that incentivize innovators to produce new ones. “The reason why so few antibiotics are being developed is simple – the market is broken. Estimates…

On behalf of the team at BIO, we send our deepest condolences to the family of Dr. John Holaday who tragically passed away. Dr. Holaday’s career was nothing short of inspiring. After earning his Ph.D. from the University of California, San Francisco School of Medicine, he served at the Walter Reed…